Sermorelin and tesamorelin are the same hormone fragment at two different lengths, with one chemical difference that decides everything else. Both are analogues of growth-hormone-releasing hormone. Sermorelin is the first 29 residues of it, unmodified. Tesamorelin is all 44, with a small fatty group bolted to the N-terminus. That group is why one lasts minutes and the other lasts hours, and it is the reason they are not interchangeable in an experiment.
Where each comes from
Native GHRH is 44 residues, and the first 29 carry essentially all of its receptor activity — the C-terminal fifteen contribute little to binding. That observation produced sermorelin: GRF(1–29), amidated at the C-terminus, otherwise the native sequence. It is the minimal active fragment, and it inherits the native hormone's weakness along with its activity.
That weakness is position two. GHRH begins Tyr-Ala-, and an alanine at position two is the signature dipeptidyl peptidase-4 looks for. The enzyme cleaves after it within minutes, and the truncated product is inactive.
What does the hexenoyl group on tesamorelin do?
It caps the N-terminus. Tesamorelin is the full 44-residue sequence with a trans-3-hexenoic acid attached to the terminal tyrosine, which blocks the free amino group DPP-4 needs to recognise its cleavage site. The enzyme cannot bind, the peptide survives, and the half-life extends from minutes to hours. It is a capping strategy rather than a substitution — one of the four standard routes — and it leaves the sequence itself native, which matters for how the receptor sees it.
| Sermorelin | Tesamorelin | |
|---|---|---|
| Sequence | GRF(1–29)-NH2 | GRF(1–44)-NH2 |
| Residues | 29 | 44 |
| N-terminal modification | None | trans-3-hexenoyl |
| DPP-4 susceptible | Yes, at Ala2 | Largely protected |
| Half-life scale | Minutes | Hours |
| Approx. mass | 3,358 Da | 5,136 Da |
Is tesamorelin more potent than sermorelin?
At the receptor, no — and this is the distinction that the half-life difference obscures. Both present essentially the same binding region to the GHRH receptor, and their affinities are comparable. Tesamorelin produces a larger integrated effect in a living system because it persists, not because each molecule does more. In a receptor assay with no proteases present, the two should look alike; if they do not, the difference is worth investigating rather than reporting.
Choosing between them
The choice follows from the research question, and it is a question about time rather than about strength.
Sermorelin suits work where a brief, pulse-shaped stimulus is the point — anything studying the pattern of a response rather than its magnitude, or anything that needs the stimulus to be gone quickly so a second one can be applied. Its short life is a feature in that design. The same logic applies further up the axis, where kisspeptin-10 is used precisely because it is the native, short-lived fragment.
Tesamorelin suits work needing sustained receptor engagement over hours, or systems containing DPP-4 activity where sermorelin would simply not survive long enough to act. In a protease-containing system, comparing the two is largely comparing intact peptide against degraded peptide.
Where does CJC-1295 sit relative to these two?
As a third approach to the same problem. CJC-1295 without DAC is GRF(1–29) with four residue substitutions that resist degradation — a substitution strategy rather than a capping one. With DAC, it adds a covalent albumin-binding group and extends persistence to days. All three belong to the GHRH-analogue group, and they form a series by duration: sermorelin in minutes, tesamorelin in hours, CJC-1295 with DAC in days. Here it is carried in co-formulation with ipamorelin, which belongs to the other secretagogue group entirely.
Why are these so often paired with ipamorelin?
Because ipamorelin acts at a different receptor. GHRH analogues engage the GHRH receptor; ipamorelin engages the ghrelin receptor. The two pathways converge on the same downstream event, so combining them addresses two inputs rather than doubling one — tesamorelin with ipamorelin is the sustained version of that pairing. The usual caveats of a co-formulated product apply: the ratio is fixed at manufacture, and the certificate has to report each component separately. Which ghrelin-side compound sits in the pairing, and why it is usually ipamorelin, is a question of selectivity.
Do the two need different handling?
Only at the edges. Both are soluble in water, neither carries a free cysteine, and both are long enough to have some conformational preference, which makes repeated freeze–thaw worth avoiding. Sermorelin's specific exposure is proteolytic: any medium containing DPP-4 activity — serum, conditioned medium from many cell types — will degrade it during the experiment, so timing between addition and readout is a variable, not a detail. Tesamorelin's specific exposure is its length: at 44 residues it is more prone to aggregation at high concentration than the 29-residue fragment, so stocks are best kept dilute enough to stay clear.
What do the C-terminal fifteen residues of GHRH actually do?
Less than their length suggests, which is why sermorelin exists at all. The receptor-binding determinants sit in the first 29 residues, and truncating the rest costs little affinity. What the C-terminal stretch appears to contribute is stability of the hormone's helical conformation in solution and some resistance to proteolysis from that end — properties that matter to a native hormone circulating for minutes and matter less to a synthetic fragment used in a controlled system. Tesamorelin keeps them because its design goal was to stay as close to the native molecule as possible while capping one end. Sermorelin discards them because its design goal was the minimum that binds. Neither choice is wrong; they answer different questions about what a research tool should be.
All products referenced here are supplied for laboratory and research use only. They are not drugs, foods, supplements or cosmetics, and are not for human or veterinary use.
